liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Jancke, Georg
Publications (10 of 10) Show all publications
Thorstenson, A., Hagberg, O., Ljungberg, B., Liedberg, F., Jancke, G., Holmäng, S., . . . Jahnson, S. (2016). Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. Scandinavian journal of urology, 50(4), 292-297
Open this publication in new window or tab >>Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer
Show others...
2016 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, no 4, p. 292-297Article in journal (Refereed) Published
Abstract [en]

AbstractObjective: The aim of this investigation was to describe tumour characteristics, treatments and survival in patients with urinary bladder cancer (UBC) in a national population-based cohort, with special reference to gender-related differences. Material and methods: All primary UBC patients with urothelial pathology reported to the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) from 1997 to 2011 were included in the study. Groups were compared regarding tumour, node, metastasis classification, primary treatment and survival. Results: In total, 30,310 patients (74.9% male, 25.1% female) with UBC were analysed. A larger proportion of women than men had stage T2?T4 (p?<?0.001), and women also had more G1 tumours (p?<?0.001). However, compared to women, a larger proportion of men with carcinoma in situ or T1G3 received intravesical treatment with bacillus Calmette?Guérin or intravesical chemotherapy, and a larger proportion of men with stage T2?T4 underwent radical cystectomy (38% men vs 33% women, p?<?0.0001). The cancer-specific survival at 5 years was 77% for men and 72% for women (p?<?0.001), and the relative survival at 5 years was 72% for men and 69% for women (p?<?0.001). Conclusions: In this population-based cohort comprising virtually all patients diagnosed with UBC in Sweden between 1997 and 2011, female gender was associated with inferior cancer-specific and relative survival. Although women had a higher rate of aggressive tumours, a smaller proportion of women than men received optimal treatment.

Place, publisher, year, edition, pages
Taylor & Francis, 2016
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-126663 (URN)10.3109/21681805.2016.1158207 (DOI)000379024000009 ()27002743 (PubMedID)
Available from: 2016-04-01 Created: 2016-04-01 Last updated: 2018-03-20
Jahnson, S., Hosseini Aliabad, A., Holmang, S., Jancke, G., Liedberg, F., Ljungberg, B., . . . Rosell, J. (2016). Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. Scandinavian journal of urology, 50(1), 14-20
Open this publication in new window or tab >>Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment
Show others...
2016 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, no 1, p. 14-20Article in journal (Refereed) Published
Abstract [en]

Objective. The aim of this study was to use the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) to investigate changes in patient and tumour characteristics, management and survival in bladder cancer cases over a period of 15 years. Materials and methods. All patients with newly detected bladder cancer reported to the SNRUBC during 1997-2011 were included in the study. The cohort was divided into three groups, each representing 5 years of the 15 year study period. Results. The study included 31,266 patients (74% men, 26% women) with a mean age of 72 years. Mean age was 71.7 years in the first subperiod (1997-2001) and 72.5 years in the last subperiod (2007-2011). Clinical T categorization changed from the first to the last subperiod: Ta from 45% to 48%, T1 from 21.6% to 22.4%, and T2-T4 from 27% to 25%. Also from the first to the last subperiod, intravesical treatment after transurethral resection for T1G2 and T1G3 tumours increased from 15% to 40% and from 30% to 50%, respectively, and cystectomy for T2-T4 tumours increased from 30% to 40%. No differences between the analysed subperiods were found regarding relative survival in patients with T1 or T2-T4 tumours, or in the whole cohort. Conclusions. This investigation based on a national bladder cancer registry showed that the age of the patients at diagnosis increased, and the proportion of muscle-invasive tumours decreased. The treatment of all tumour stages became more aggressive but relative survival showed no statistically significant change over time.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2016
Keywords
Bladder cancer; population-based; survival
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-124469 (URN)10.3109/21681805.2015.1085089 (DOI)000367832000004 ()26382667 (PubMedID)
Available from: 2016-02-02 Created: 2016-02-01 Last updated: 2017-11-30
Jancke, G., Rosell, J. & Jahnson, S. (2016). Tumour location adjacent to the ureteric orifice in primary Ta/T1 bladder cancer is predictive of recurrence. Scandinavian journal of urology, 50(1), 33-38
Open this publication in new window or tab >>Tumour location adjacent to the ureteric orifice in primary Ta/T1 bladder cancer is predictive of recurrence
2016 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, no 1, p. 33-38Article in journal (Refereed) Published
Abstract [en]

Objective: The aim of this study was to evaluate tumour growth located around the ureteric orifice (LUO) at primary diagnosis of Ta/T1 urinary bladder cancer in relation to effects on recurrence and progression. Materials and methods: Clinical and pathological characteristics of patients diagnosed with primary Ta/T1 urinary bladder cancer from 1992 to 2007 were recorded prospectively. Location of the primary tumour and growth around the ureteric orifice (within 1 cm) were recorded and correlated with recurrence and progression during further follow-up. Hazard ratios (HRs) were estimated using Cox regression with 95% confidence intervals (CIs) in both univariate and multivariate analysis. Results: The study included 768 evaluable patients with a median follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Growth of a primary tumour adjacent to the ureteric orifice was associated with recurrence (HR = 1.28, 95% CI = 1.07-1.54) but not progression (HR = 1.04, 95% CI = 0.65-1.67). The most common location of the first recurrence was the posterior bladder wall (29%). Other locations in the bladder did not predict recurrence or progression. Additional factors affecting recurrence were tumour size greater than 15mm, T1 tumour category, multiplicity, malignant or missing/not representative bladder wash cytology and surgery performed by residents. Conclusions: A primary tumour located around the ureteric orifice was predictive of recurrence, which could be taken into account in future follow-up schedules.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2016
Keywords
Bladder cancer; recurrence; tumour location; ureteric orifice
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-124470 (URN)10.3109/21681805.2015.1066849 (DOI)000367832000007 ()26202687 (PubMedID)
Available from: 2016-02-02 Created: 2016-02-01 Last updated: 2017-11-30
Liedberg, F., Hagberg, O., Holmang, S., Hosseini Aliabad, A., Jancke, G., Ljungberg, B., . . . Jahnson, S. (2015). Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scandinavian journal of urology, 49(4), 290-295
Open this publication in new window or tab >>Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study
Show others...
2015 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 49, no 4, p. 290-295Article in journal (Refereed) Published
Abstract [en]

Objective. The aim of this study was to investigate recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) in a large population-based setting. Materials and methods. Patients with bladder cancer (stage Ta, T1 or carcinoma in situ) diagnosed in 2004-2007 (n = 5839) in Sweden were investigated 5 years after diagnosis using a questionnaire. Differences in time to recurrence and progression were analysed in relation to age, gender, tumour stage and grade, intravesical treatment, healthcare region, and hospital volume of NMIBC patients (stratified in three equally large groups). Results. Local bladder recurrence and progression occurred in 50 and 9% of the patients, respectively. The rate of local recurrence was 56% in the southern healthcare region compared to 37% in the northern region. A multivariate Cox proportional hazards model, adjusting for age, gender, tumour stage and grade, intravesical treatment, healthcare region and hospital volume, showed that recurrence was associated with TaG2 and T1 disease, no intravesical treatment and treatment in the southern healthcare region, but indicated a lower risk of recurrence in the northern healthcare region. Adjusting for the same factors in a multivariate analysis suggested that increased relative risk of progression correlated with older age, higher tumour stage and grade, and diagnosis in the Uppsala/Orebro healthcare region, whereas such risk was decreased by intravesical treatment (relative risk 0.72, 95% confidence interval 0.55-0.93, p = 0.012). Conclusions. The incidence of NMIBC recurrence and progression was found to be high in Sweden, and important disparities in outcome related to care patterns appear to exist between different healthcare regions.

Place, publisher, year, edition, pages
Informa Healthcare, 2015
Keywords
Bladder cancer; non-muscle-invasive; progression; recurrence
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-120870 (URN)10.3109/21681805.2014.1000963 (DOI)000359170200004 ()25624049 (PubMedID)
Available from: 2015-08-28 Created: 2015-08-28 Last updated: 2017-12-04
Jancke, G., Rosell, J. & Jahnson, S. (2014). Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer. SCANDINAVIAN JOURNAL OF UROLOGY, 48(3), 276-283
Open this publication in new window or tab >>Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer
2014 (English)In: SCANDINAVIAN JOURNAL OF UROLOGY, ISSN 2168-1805, Vol. 48, no 3, p. 276-283Article in journal (Refereed) Published
Abstract [en]

Introduction: To evaluate the impact of experience in transurethral resection of bladder tumor (TUR-BT) on recurrence and progression in primary Ta/T1 urinary bladder cancer.

Methods: Clinical and pathological characteristics of patients with primary Ta/T1 urinary bladder cancer were recorded prospectively from 1992 to 2007 inclusive. Data on surgeons’ experience were categorized as follows: (a) experience by training status (residents or specialists); (b) number of TUR-BTs performed by each surgeon during the registration period, with cut-off levels at > 100, > 150, > 200, > median, and > third quartile of surgical volume; (c) lifetime high-volume surgeons (> 100 TUR-BTs). Hazard ratios (HRs) were estimated using Cox regression with 95% confidence intervals (CIs) in both univariate and multivariate analysis.

Results: The analysis included 768 evaluable patients with a median follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Surgery was performed by residents in 100 cases and specialists in 668, with recurrence in 75 (75%) and 403 (60%) patients, and progression in 9 (9%) and 62 (9%), respectively. Surgery performed by residents was statistically associated with recurrence (HR = 0.69, 95% CI = 0.54-0.89) but not progression (HR = 0.72, 95% CI = 0.35-1.48). Surgical volume (b and c) was not found to have a significant impact on recurrence or progression in any of the analyses at the chosen cut-offs.

Conclusions: Surgical experience (specialist/resident) was a predictive factor for recurrence after TUR-BT for Ta/T1 bladder cancer. However, surgeon volume was not associated with recurrence at the chosen cut-off levels. Training programs, checklist

Place, publisher, year, edition, pages
Informa Healthcare, 2014
National Category
Clinical Medicine Surgery Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-89145 (URN)10.3109/21681805.2013.864327 (DOI)000336457500007 ()
Available from: 2013-02-22 Created: 2013-02-22 Last updated: 2015-04-01Bibliographically approved
Jancke, G. (2013). Aspects of Recurrence and Progression in Ta/T1 Urinary Bladder Cancer. (Doctoral dissertation). Linköping: Linköping University Electronic Press
Open this publication in new window or tab >>Aspects of Recurrence and Progression in Ta/T1 Urinary Bladder Cancer
2013 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Aims: To evaluate different aspects of recurrence and, when appropriate, progression in primary Ta/T1 urinary bladder cancer.

Patients and methods: All evaluable patients diagnosed with primary Ta/T1 urinary bladder cancer in Linköping and Norrköping between 1992 and 2007 were included prospectively in the study cohort. Histopathology results were classified according to the TNM system and were reviewed by a reference pathologist using the WHO 1999 criteria (except in the studies reported in Papers I and IV). Risk factors for local recurrence were evaluated using data from the period 1992–2001 (Paper I). Tumour size (Paper II) and bladder wash cytology (Paper III) at primary diagnosis were assessed regarding the impact on recurrence and progression, and tumour presence in the marginal resection in primary and recurrent Ta/T1 bladder cancer was investigated considering effects on recurrence in patients treated between 2001 and 2010 (Paper IV). Furthermore, surgical experience measured as training status (resident or specialist) and surgical volume (both during the study period and lifetime) were analysed regarding their influence on recurrence and progression (Paper V).

Results: Tumour size > 30 mm (p < 0.001) and multiplicity (p = 0.021) were significantly associated with local recurrence (Paper I). Tumour sizes 16–30 mm and > 30 mm were correlated with recurrence (p = 0.003 and p < 0.001, respectively) but not with progression (Paper II). High-grade malignant bladder wash cytology proved to be predictive of both recurrence (p < 0.001) and progression (p = 0.036) as was shown in Paper III. A tumour-positive marginal resection was related to overall (p < 0.001) and local (p < 0.001) recurrence (Paper IV). Transurethral resection of bladder tumours performed by residents was associated with recurrence (p = 0.004) but not with progression. No differences in relation to either recurrence or progression were found for the surgical volume approach at the chosen cut-offs (Paper V).

Conclusions: The present studies identified new risk factors for recurrence (tumours > 15 mm, high-grade bladder wash cytology at diagnosis, tumour-positive marginal resection, and surgery performed by residents) and progression (local recurrence and high-grade malignant bladder wash cytology at diagnosis), which in the future may be integrated into follow-up schedules or risk profiles for patients with Ta/T1 urinary bladder cancer.

Place, publisher, year, edition, pages
Linköping: Linköping University Electronic Press, 2013. p. 81
Series
Linköping University Medical Dissertations, ISSN 0345-0082 ; 1344
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-89146 (URN)978-91-7519-738-8 (ISBN)
Public defence
2013-03-22, Eken salen, Hälsouniversitet, Campus US, Linköpings universitet, Linköping, 13:00 (Swedish)
Opponent
Supervisors
Available from: 2013-02-22 Created: 2013-02-22 Last updated: 2015-06-05Bibliographically approved
Jancke, G., Rosell, J., Chebil, G. & Jahnson, S. (2012). Bladder Wash Cytology at Diagnosis of Ta-T1 Bladder Cancer Is Predictive for Recurrence and Progression. Urology, 80(3), 625-631
Open this publication in new window or tab >>Bladder Wash Cytology at Diagnosis of Ta-T1 Bladder Cancer Is Predictive for Recurrence and Progression
2012 (English)In: Urology, ISSN 0090-4295, E-ISSN 1527-9995, Vol. 80, no 3, p. 625-631Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE To evaluate the effect of the bladder wash cytology finding at the primary diagnosis of Stage Ta-T1 urinary bladder cancer on recurrence and progression. less thanbrgreater than less thanbrgreater thanMETHODS The clinical and pathologic characteristics of all patients with primary Stage Ta-T1 urinary bladder cancer were prospectively registered. The data were divided according to the bladder wash cytology results at diagnosis. Multivariate analyses were performed to determine the influence of bladder wash cytology on recurrence and progression. less thanbrgreater than less thanbrgreater thanRESULTS The analysis included 768 evaluable patients with a mean follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). High-grade malignant bladder wash cytology was predictive for recurrence and progression (P andlt; .001 and P = .036, respectively). Other factors affecting recurrence were missing bladder wash cytology data, tumors size 16-30 mm and andgt;30 mm, Stage T1 tumor category, and multiplicity (P = .008, P = .006, P andlt; .001, P = .002, and P andlt; .001, respectively). Progression was also associated with T1 tumor category, local recurrence, and primary concomitant carcinoma in situ (P andlt; .001, P andlt; .001, and P = .024, respectively). less thanbrgreater than less thanbrgreater thanCONCLUSION High-grade malignant bladder wash cytology at the primary diagnosis was predictive for recurrence and progression. This could be taken into account in designing future follow-up schedules.

Place, publisher, year, edition, pages
Elsevier, 2012
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-82061 (URN)10.1016/j.urology.2012.04.049 (DOI)000308373000035 ()
Available from: 2012-10-01 Created: 2012-09-28 Last updated: 2017-12-07
Jancke, G., Rosell, J. & Jahnson, S. (2012). Residual tumour in the marginal resection after a complete transurethral resection is associated with local recurrence in Ta/T1 urinary bladder cancer. Scandinavian Journal of Urology and Nephrology, 46(5), 343-347
Open this publication in new window or tab >>Residual tumour in the marginal resection after a complete transurethral resection is associated with local recurrence in Ta/T1 urinary bladder cancer
2012 (English)In: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, E-ISSN 1651-2065, Vol. 46, no 5, p. 343-347Article in journal (Refereed) Published
Abstract [en]

Objective. This study investigated the presence of residual tumour in the marginal resection (MR) after a complete transurethral resection (TURB) of Ta/T1 transitional urinary bladder cancer. The association between positive MR and recurrence was analysed. Material and methods. After macroscopically complete TURB, a marginal resection of 7 mm (corresponding to the diameter of the resection loop) was removed around the entire resection area. Univariate and multivariate Cox regression analyses were performed to assess the influence of residual disease on recurrence. Results. In all, 94 patients with a median follow-up time of 36 months were included, and residual tumour in the MR was present in 24 (26%). The recurrence rates for all cases, for those with a tumour-positive and a tumour-free MR were 60 (64%), 20 (83%) and 40 (57%), respectively. Local recurrence was found in 14 (58%) of the patients with tumour presence in the MR compared to 13 (19%) of those with a tumour-free margin. A positive MR was significantly associated with overall recurrence (p andlt; 0.001) and local recurrence (p = 0.001). Conclusion. Incomplete transurethral resection of bladder cancer is common, as demonstrated in 26% patients with positive MR. The presence of tumour in the MR may be a risk factor for recurrence, and particularly local recurrence.

Place, publisher, year, edition, pages
Informa Healthcare, 2012
Keywords
edge of resection area, marginal resection, recurrence, residual tumour, Ta/T1 urinary bladder cancer, TURB
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-84884 (URN)10.3109/00365599.2012.684700 (DOI)000308951000005 ()
Available from: 2012-11-01 Created: 2012-10-26 Last updated: 2017-12-07
Jancke, G., Rosell, J. & Jahnson, S. (2011). Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology, 45(6), 388-392
Open this publication in new window or tab >>Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder
2011 (English)In: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, E-ISSN 1651-2065, Vol. 45, no 6, p. 388-392Article in journal (Refereed) Published
Abstract [en]

Objective. This study aimed to evaluate the impact of tumour size on recurrence and progression in a population-based series of non-muscle-invasive bladder cancers. Material and methods. Clinical and pathological characteristics of patients with primary Ta/bladder cancer were registered. The patients tumours were categorized by size into five size groups (1-10, 11-20, 21-30, 31-40 and andgt;40 mm) or three size groups (1-15, 16-30 and andgt;30 mm). Results. The analysis included 768 evaluable patients with a mean follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Tumour size was associated with recurrence for tumours sized 21-30, 31-40 and andgt;40 mm (p = 0.03, p andlt; 0.001, p andlt; 0.001, respectively) in the five size group and for tumours sized 16-30 and andgt;30 mm (p = 0.003 and p andlt; 0.001) in the three size group. Other factors affecting recurrence were T1 tumour category, multiplicity and surgery performed by residents (p andlt; 0.001, p andlt; 0.001, p = 0.002, respectively). Considering progression, there was no significant association with tumour size, and T1 category and local recurrence were the only significant risk factors (both p andlt; 0.001). Conclusion. Tumour size andlt;= 15 mm is associated with a lower risk of recurrence but not progression. Dividing tumour size into three size groups gives additional information compared with two size groups with cut-off at 30 mm.

Place, publisher, year, edition, pages
Informa Healthcare, 2011
Keywords
progression, recurrence, tumour size, urinary bladder cancer
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-72650 (URN)10.3109/00365599.2011.590995 (DOI)000296871900003 ()
Available from: 2011-12-02 Created: 2011-12-02 Last updated: 2017-12-08
Jancke, G., Damm, O., Rosell, J. & Jahnson, S. (2008). Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer. Scandinavian Journal of Urology and Nephrology, 42(5), 417-421
Open this publication in new window or tab >>Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer
2008 (English)In: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, E-ISSN 1651-2065, Vol. 42, no 5, p. 417-421Article in journal (Refereed) Published
Abstract [en]

Objective. This study evaluated risk factors for local tumour recurrence, defined as recurrence at the same location in the bladder within 18 months after primary resection in patients with newly diagnosed pTa or pT1 bladder cancer. Patients and methods. The study included 472 patients with newly diagnosed pTa/T1 bladder cancer between 1992 and 2001. The patients were followed prospectively in accordance with a control programme and possible risk factors for tumour recurrence were registered. Results. Local tumour recurrence was observed in 164 (35%) patients, another 117 (25%) patients had recurrence at other locations in the bladder (non-local recurrence) and 191 (40%) had no recurrence at all. Tumour size and multiple tumours were significantly associated with a higher risk for developing local recurrence as opposed to non-local recurrence. Tumour category was of borderline statistical significance. Gender and tumour grade were not found to be risk factors for developing local recurrence. Conclusion. Tumour size and multiplicity are risk factors for development of recurrence at the same location in the bladder as the primary tumour. Local tumour recurrence may be a result of non-radical primary transurethral resection. One may consider recommending standard re-resection within 6-8 weeks in patients with tumours >3 cm or those with multiple primary tumours. © 2008 Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS).

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-43347 (URN)10.1080/00365590802016302 (DOI)73621 (Local ID)73621 (Archive number)73621 (OAI)
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2017-12-13
Organisations

Search in DiVA

Show all publications